Badger Meter Inc vs Quest Diagnostics Inc — how do they compare? Badger Meter Inc trades at $141.44 (market cap $4.13B), while Quest Diagnostics Inc trades at $204.98 (market cap $22.80B). The key difference: Quest Diagnostics Inc is far larger — about 5.5× Badger Meter Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| BMI | DGX | |
|---|---|---|
Market Cap | $4.13B | $22.80B |
Sector | Technology | Health |
52-Week High | $245.81 | $216.02 |
52-Week Low | $113.41 | $166.42 |
Enterprise Value | $3.92B | $28.82B |
Dividend Yield | 1.13% | 1.67% |
Signals from Pluang's Aura AI — not financial advice
Badger Meter (BMI) trades at $140.12, down 2.82% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported $917M revenue and $142M net income for 2025, with strong profitability margins but recent earnings misses in Q4 2025 and Q1 2026. A securities class action lawsuit filed in July 2026 adds significant near-term uncertainty, though analyst consensus remains a Buy with a $144.60 price target.
The stock faces headwinds from legal risks and earnings volatility, but solid fundamentals and analyst support suggest potential recovery if legal concerns subside. Investors should weigh the high valuation multiples against operational strength and monitor lawsuit developments closely for directional cues.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.
Read more on BMI →Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →